Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3...
3D Signatures’ (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) non-brokered private placement has been fully subscribed for and has closed for gross proceeds of $1,622,673. The private placement involved the sale of 8,113,365 units at...
Vital Therapies (NASDAQ:VTL) has been selected for addition to the NASDAQ biotechnology index, effective prior to the opening on Dec. 18. Companies in the index must meet eligibility requirements, including minimum...
A peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that Ortho Regenerative Technologies’ (CSE:ORTH) Ortho-R hybrid implants release more growth factors and...
Closely-held NeuroproteXeon announced the publication of a second finding from a randomized, controlled Phase 2 trial of inhaled xenon and oxygen, combined with hypothermia, for out-of-hospital cardiac arrest (OHCA)...
Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a binding term sheet with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, giving Molteni an exclusive license to commercialize Probuphine...
Closely-held Spartan Bioscience has launched the Spartan Legionella Detection System, the first on-site DNA test for Legionella that can detect and quantify Legionella bacteria in 45 minutes. The system consists of a...
The European Medicines Agency has accepted for review Titan Pharmaceuticals’ (NASDAQ:TTNP) marketing authorization application (MAA) for Probuphine. The acceptance marks the beginning of the EMA’s regulatory...
BioLight Life Sciences (TASE:BOLT) and other shareholders of its subsidiary, IOPtima, entered into a binding agreement for the investment and acquisition in stages of IOPtima by Chengdu Kanghong Pharmaceutical Group of...
BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The study is designed to evaluate...
Oramed Pharmaceuticals (NASDAQ:ORMP) received approval from Israel’s Ministry of Health to initiate an exploratory clinical study of its oral insulin capsule, ORMD-0801, in patients with nonalcoholic...
Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry...
Cellect Biotechnology (NASDAQ, TASE:APOP) CEO, Dr. Shai Yarkoni, was selected to provide the keynote presentation at the 11th World Congress of Regenerative Medicine and Stem Cell Technologies in Singapore. The event is...
Profound Medical (OTCQX:PRFMF; TSXV:PRN) announced that benign prostatic hyperplasia (BPH) treatments utilizing TULSA-PRO are now being successfully conducted in Germany. BPH is a non-cancerous enlargement of the...
Flex Pharma (NASDAQ:FLKS) announced positive topline data for FLX-787 from its placebo-controlled, crossover Australian trial in amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps. The study was...
The European Patent Office has issued to Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) a notice of intent to grant a patent for broader claims for its invention titled, “Methods and Compositions for Oral Administration of...
Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid...
An article published in the journal, Immunity & Aging, suggests that the leukotriene receptor antagonist, Montelukast, rejuvenates aged brains in rats. The authors of the article question whether the commonly used...
Titan Pharmaceuticals (NASDAQ:TTNP) presented non-clinical data on the use of its ProNeura subdermal implant for the long-term, sustained delivery of liothyronine (L-T3) at the annual conference of the American Thyroid...
Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...
An investigator-led clinical trial has successfully treated its first patient in a study of BioTime’s (NYSE MKT: BTX) Premvia as a carrier for stromal vascular fraction cells (SVF) for the treatment of age-related...
Titan Pharmaceuticals (NASDAQ:TTNP) has treated the first patient in a Phase 1/2 trial of its ropinirole implant intended for the treatment of signs and symptoms of idiopathic Parkinson’s disease (PD). Ropinirole...